{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-004517","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2025-01-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.402296+00:00","generated_at":"2026-05-27T23:03:39.692360+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nasdaq bid price compliance regained; equity compliance deadline extended to May 19","bullets":["Cara regained Nasdaq minimum bid price compliance after 1-for-12 reverse stock split effective Dec 30; letter received Jan 16.","Stockholders' equity of $707k at Sep 30 below $2.5M minimum; extension granted to May 19, 2025.","Extension conditional on closing proposed merger with Tvardi, which is expected to meet initial listing criteria.","Company must also satisfy all applicable Nasdaq initial listing standards at merger close."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-004517","json":"https://secwatch.observer/filing/0001104659-25-004517.json","markdown":"https://secwatch.observer/filing/0001104659-25-004517.md","text":"https://secwatch.observer/filing/0001104659-25-004517.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465925004517/0001104659-25-004517-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465925004517/tm2430195d6_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T23:03:39.692360+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}